Arcoma AB (SE:ARCOMA)
:ARCOMA
Top Page
Arcoma AB
(ARCOMA)
Select Model
Select Model
Rating:68Neutral
Price Target:
kr8.50
▲(18.06% Upside)
Action:ReiteratedDate:02/18/26
The score is primarily supported by improved financial strength—zero debt and strong recent cash generation—partly offset by weakening top-line momentum and notable 2025 gross profit compression. Technicals are neutral-to-mixed and valuation (P/E 21.44 with no dividend) does not provide a clear margin of safety.
Positive Factors
Debt-free balance sheet
Arcoma's reduction of total debt to effectively zero materially improves financial flexibility and reduces solvency and interest-rate risk. Over 2–6 months this supports funding for product support, modest capex or targeted M&A without reliance on external financing, improving resilience.
Negative Factors
Weakening revenue trend
Falling revenue in consecutive years undermines long-term durability: it pressures margins, limits scale benefits, and may signal weakening demand or competitive pressure in the imaging market. Sustained top-line declines would erode recent cash improvements without a clear recovery plan.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Arcoma's reduction of total debt to effectively zero materially improves financial flexibility and reduces solvency and interest-rate risk. Over 2–6 months this supports funding for product support, modest capex or targeted M&A without reliance on external financing, improving resilience.
Read all positive factors
Arcoma AB (ARCOMA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr122.48M
Dividend YieldN/A
Average Volume (3M)22.73K
Price to Earnings (P/E)20.9
Beta (1Y)0.15
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees31
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.10
Shares Outstanding14,308,510
10 Day Avg. Volume31,356
30 Day Avg. Volume22,732
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.41
Price to Sales (P/S)0.80
P/FCF Ratio5.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.65
Revenue Forecast (FY)kr140.00M
Arcoma AB Business Overview & Revenue Model
Company Description
Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus ...
How the Company Makes Money
Arcoma makes money primarily by selling digital radiography (X-ray) equipment and related imaging solutions to customers in the healthcare market. Revenue is generated from (1) system/equipment sales (e.g., complete X-ray room solutions or radiogr...
Arcoma AB Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
86
Very Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 130.80M | 156.81M | 163.01M | 125.05M | 117.13M |
| Gross Profit | 6.86M | 62.61M | 57.91M | 50.45M | 41.65M |
| EBITDA | 16.02M | 21.96M | 6.11M | 4.68M | -6.66M |
| Net Income | 5.03M | 11.18M | 2.56M | 1.90M | -7.47M |
Balance Sheet | |||||
| Total Assets | 96.65M | 80.46M | 81.96M | 100.33M | 79.27M |
| Cash, Cash Equivalents and Short-Term Investments | 35.32M | 13.38M | 5.00M | 9.66M | 4.83M |
| Total Debt | 0.00 | 0.00 | 3.87M | 25.09M | 16.61M |
| Total Liabilities | 21.92M | 21.13M | 33.30M | 54.46M | 35.23M |
| Stockholders Equity | 74.73M | 59.33M | 48.66M | 45.88M | 44.04M |
Cash Flow | |||||
| Free Cash Flow | 18.50M | 12.06M | 16.61M | -4.35M | -6.12M |
| Operating Cash Flow | 18.72M | 18.84M | 19.16M | -179.00K | -1.93M |
| Investing Cash Flow | -5.62M | -6.78M | -2.55M | -4.17M | -4.19M |
| Financing Cash Flow | 10.36M | -3.87M | -21.22M | 9.65M | 2.40M |
Arcoma AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:ARCOMA
Arcoma AB
8.56
0.18
2.15%
DE:LS60
Clinical Laserthermia Systems AB Class B
0.36
0.15
74.63%
DE:2OK
SpectraCure AB
0.01
-0.04
-80.00%
DE:LUR
Luxbright AB
0.01
-0.05
-78.33%
DE:5YL
BrainCool AB
0.03
-0.10
-75.94%
SE:NEOLA
Neola Medical AB
0.72
-1.87
-72.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.